Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e6.

PMID:
30954567
2.

Burden of disease in patients with chronic hepatitis C in the Austrian REAL study.

Gschwantler M, Bamberger T, Graziadei I, Maieron A, Katalinic N, Stauber R.

Wien Klin Wochenschr. 2019 Jan;131(1-2):8-16. doi: 10.1007/s00508-018-1404-2. Epub 2018 Nov 14.

PMID:
30430232
3.

Increased KCNJ18 promoter activity as a mechanism in atypical normokalemic periodic paralysis.

Soufi M, Ruppert V, Rinné S, Mueller T, Kurt B, Pilz G, Maieron A, Dodel R, Decher N, Schaefer JR.

Neurol Genet. 2018 Oct 3;4(5):e274. doi: 10.1212/NXG.0000000000000274. eCollection 2018 Oct.

4.

Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study.

Pfisterer N, Riedl F, Pachofszky T, Gschwantler M, König K, Schuster B, Mandorfer M, Gessl I, Illiasch C, Fuchs EM, Unger L, Dolak W, Maieron A, Kramer L, Madl C, Trauner M, Reiberger T.

Liver Int. 2019 Feb;39(2):290-298. doi: 10.1111/liv.13971. Epub 2018 Oct 17.

5.

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.

Flamm S, Reddy KR, Zadeikis N, Hassanein T, Bacon BR, Maieron A, Zeuzem S, Bourliere M, Calleja JL, Kosloski MP, Oberoi RK, Lin CW, Yu Y, Lovell S, Semizarov D, Mensa FJ.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):527-535.e6. doi: 10.1016/j.cgh.2018.07.003. Epub 2018 Sep 10.

6.

Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.

Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H.

Liver Int. 2018 Jul;38(7):1188-1197. doi: 10.1111/liv.13652. Epub 2018 Jan 31.

PMID:
29197145
7.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
8.

Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.

Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P.

Liver Int. 2018 Jun;38(6):1028-1035. doi: 10.1111/liv.13629. Epub 2017 Dec 1.

PMID:
29136329
9.

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P.

Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158. doi: 10.1007/s00508-017-1262-3. Epub 2017 Oct 23.

10.

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Gschwantler M, Laferl H, Vogel W, Korak W, Moser S, Hofer H, Bauer B, Schleicher M, Bognar B, Bischof M, Stauber R, Maieron A, Ferenci P; Austrian Hepatitis Study Group.

Wien Klin Wochenschr. 2018 Jan;130(1-2):54-61. doi: 10.1007/s00508-017-1263-2. Epub 2017 Sep 12.

PMID:
28900714
11.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators.

N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.

12.

Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals.

Kozbial K, Aberle SW, Susser S, Al-Zoairy R, Moser S, Stättermayer AF, Maieron A, Gschwantler M, Stauber R, Graziadei I, Zoller H, Beinhardt S, Holzmann H, Munda-Steindl P, Hofer H, Sarrazin C, Ferenci P.

Aliment Pharmacol Ther. 2017 Jan;45(2):373-375. doi: 10.1111/apt.13887. Epub 2016 Dec 1. No abstract available.

13.

von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.

Rutter K, Etschmaier A, Ferlitsch M, Maieron A, Hametner S, Horvatits T, Paternostro R, Salzl P, Reiberger T, Peck-Radosavljevic M, Quehenberger P, Hofer H, Trauner M, Ferenci P, Ferlitsch A.

Dig Liver Dis. 2016 Oct;48(10):1194-9. doi: 10.1016/j.dld.2016.06.033. Epub 2016 Jul 19.

PMID:
27476467
14.

Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.

Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer H, Ferenci P.

J Hepatol. 2016 Oct;65(4):856-858. doi: 10.1016/j.jhep.2016.06.009. Epub 2016 Jun 16. No abstract available.

PMID:
27318327
15.

DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.

Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stättermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A.

Transpl Int. 2016 Sep;29(9):999-1007. doi: 10.1111/tri.12799. Epub 2016 Jul 7.

16.

Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.

Stern R, Hametner S, Ramona AZ, Moser S, Karpi A, Laferl H, Stauber RE, Zoller HM, Maieron A, Vogel W, Graziadei I, Gschwantler M, Kozbial K, Freissmuth C, Hofer H, Ferenci P.

Am J Gastroenterol. 2016 May;111(5):744-5. doi: 10.1038/ajg.2016.39. No abstract available.

PMID:
27151123
17.

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.

Hametner S, Ferlitsch A, Ferlitsch M, Etschmaier A, Schöfl R, Ziachehabi A, Maieron A.

PLoS One. 2016 Feb 19;11(2):e0149230. doi: 10.1371/journal.pone.0149230. eCollection 2016.

18.

Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations.

Stättermayer AF, Traussnigg S, Dienes HP, Aigner E, Stauber R, Lackner K, Hofer H, Stift J, Wrba F, Stadlmayr A, Datz C, Strasser M, Maieron A, Trauner M, Ferenci P.

J Hepatol. 2015 Jul;63(1):156-63. doi: 10.1016/j.jhep.2015.01.034. Epub 2015 Feb 9.

PMID:
25678388
19.

Drug fever due to a single dose of pantoprazole.

Schiller D, Maieron A, Schöfl R, Donnerer J.

Pharmacology. 2014;94(1-2):78-9. doi: 10.1159/000364781. Epub 2014 Sep 13.

PMID:
25228460
20.

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group.

J Hepatol. 2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022. Epub 2014 Jul 24.

PMID:
25064437

Supplemental Content

Loading ...
Support Center